Lead Product(s): TAK-831
Therapeutic Area: Psychiatry/Psychology Product Name: TAK-831
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Neurocrine Biosciences
Deal Size: $2,015.0 million Upfront Cash: $120.0 million
Deal Type: Collaboration June 16, 2020
Under the terms of the agreement, Takeda granted an exclusive license to Neurocrine Biosciences for seven pipeline programs, including three clinical stage assets for schizophrenia, treatment-resistant depression and anhedonia.